Phase 3 Trial Results Suggest Flortaucipir Tracer Agent Can Help Predict Alzheimer’s Diagnosis

Phase 3 Trial Results Suggest Flortaucipir Tracer Agent Can Help Predict Alzheimer’s Diagnosis
Flortaucipir, an investigational imaging agent, was able to efficiently detect Tau protein aggregates and related Alzheimer's disease brain changes, meeting both of its primary objectives in a Phase 3 trial. Results of the trial revealed that flortaucipir demonstrated great sensitivity in identifying tau-related damage and predicting Alzheimer's disease diagnosis. "These encouraging results are a major advance in our ability to image the pathology of Alzheimer's disease," Mark Mintun, MD, vice president of pain and neurodegeneration research and development at Eli Lilly and Company, said in a
Subscribe or to access all post and page content.